Research progress of immune-mediated liver injury induced by immune checkpoint inhibitors
10.3760/cma.j.cn114015-20220801-00695
- VernacularTitle:免疫检查点抑制剂所致免疫介导性肝损伤研究进展
- Author:
Yan WANG
1
;
Xinyan ZHAO
1
;
Jidong JIA
1
Author Information
1. 首都医科大学附属北京友谊医院肝病中心，国家消化系统疾病临床医学研究中心，北京 100050
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Antineoplastic agents;
Drug-induced liver injury;
Programmed cell death 1 receptor;
Programmed cell death ligand 1;
Cytotoxic
- From:
Adverse Drug Reactions Journal
2023;25(4):243-247
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) play the role of anti-tumor by activating the immune system in human, but they can also cause immune-mediated liver injury, which is different from conventional drug-induced liver injury in the incidence, clinical manifestations, pathogenesis, and prognosis. The main pathogenesis is that ICIs block key nodes of negative regulation of the immune response, including cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death 1 receptor/programmed cell death ligand 1. Liver-injury occurs when the immune system is overactivated and loses immune tolerance to the liver. Immune-mediated liver injury includes immune-mediated hepatitis and immune-mediated cholangitis. Histopathological examination of the liver shows damage in hepatocytes and bile ducts, accompanied by central venous dermatitis mostly and granulomatous lesions partially. After diagnosis of immune-mediated liver injury, treatment should be given based on the severity, and glucocorticoids or immunosuppressants are often necessary.
